Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
06 February 2014Website:
http://carismatx.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 23:58:10 GMTDividend
Analysts recommendations
Institutional Ownership
CARM Latest News
Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and Björn Odlander PHILADELPHIA , July 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Marella Thorell and David Scadden, M.D.
Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company's virtual annual meeting of stockholders held on June 13, 2024 was convened and adjourned, without any business being conducted, due to technical difficulties with the third-party hosting site.
CARISMA THERAP (CARM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
-Late-breaking abstract to be presented on November 3 rd at 11:30 am PT highlighting pre-clinical data with Moderna -Two additional pre-clinical data abstracts highlighting next-generation enhancements to Carisma's cell therapy platform to be shared PHILADELPHIA , Oct. 25, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that new pre-clinical data leveraging an mRNA platform to develop in-vivo chimeric antigen receptor macrophage ("CAR-M") will be presented as a late-breaking abstract (#LBA1514) at the upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting held from Wednesday, November 1, to Sunday, November 5, 2023, in San Diego, California. Two posters highlighting next-generation enhancements to Carisma's CAR-M platform, including a custom intronic shRNA approach and data on Engineered Microenvironment Converters (EM-C), will also be presented.
To clearly set expectations from the get-go, these top stocks under $5 represent extraordinary risks. As either small or even micro-capitalization enterprises, you automatically should assume volatility when entering this arena.
What type of business is Carisma Therapeutics?
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
What sector is Carisma Therapeutics in?
Carisma Therapeutics is in the Healthcare sector
What industry is Carisma Therapeutics in?
Carisma Therapeutics is in the Biotechnology industry
What country is Carisma Therapeutics from?
Carisma Therapeutics is headquartered in United States
When did Carisma Therapeutics go public?
Carisma Therapeutics initial public offering (IPO) was on 06 February 2014
What is Carisma Therapeutics website?
https://carismatx.com
Is Carisma Therapeutics in the S&P 500?
No, Carisma Therapeutics is not included in the S&P 500 index
Is Carisma Therapeutics in the NASDAQ 100?
No, Carisma Therapeutics is not included in the NASDAQ 100 index
Is Carisma Therapeutics in the Dow Jones?
No, Carisma Therapeutics is not included in the Dow Jones index
When does Carisma Therapeutics report earnings?
The next expected earnings date for Carisma Therapeutics is 09 August 2024